Amneal Pharmaceuticals Reaps $2.5M in Kentucky Incentives
05/11/2010
"In addition to compelling economic incentives, we recognized that the superb quality and dedication of Glasgow's work force is a key factor in Amneal's reputation for service excellence, so the decision to stay and expand operations in Kentucky was an easy one," said Jim Luce, Amneal executive vice president of sales and marketing.
The Kentucky Economic Development Finance Authority has pre-approved Amneal for tax incentives up to $2.5 million through the Kentucky Business Investment program.
Amneal plans to use the funds to consolidate distribution logistics and sales in a 115,000-square-foot Glasgow facility. It will combine distribution that currently exists in Long Island, New York and Fountain Run, Kentucky. The company develops, manufactures, and distributes generic pharmaceuticals. It is the tenth largest supplier of generic drugs in the country in terms of prescriptions dispensed.
Project Announcements
Australia-Based Aquatic Leisure Technologies Group Plans Opp, Alabama, Manufacturing Operations
12/11/2025
Teradyne Plans Wixom, Michigan, Robotics Operations
12/11/2025
Robinson Plans Altoona, Iowa, Manufacturing Operations
12/11/2025
BioTouch Expands Columbus, Georgia, Operations
12/11/2025
Natrion Plans Erie County, New York, Battery Components Operations
12/11/2025
Czech-Based GZ PrintPak Expands Mount Pleasant, Wisconsin, Manufacturing Operations
12/11/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
How Canada Stays Competitive
Q3 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
America’s Aerospace Reboot
Q3 2025